Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System
Invivoscribe, a global leader in precision diagnostics, has announced the launch of an Immune Biomarker Discovery grant program, focused on supporting development, validation and deployment of novel applications for use of their distributed LymphoTrack® NGS products and bioinformatics software.
Massively parallel sequencing coupled with reagents targeting the immune receptor loci have accelerated our understanding of the immune response and immunology related disease processes. The availability of distributed RUO LymphoTrack tests and bioinformatics have eliminated a majority of the barriers of a service model approach, and have accelerated the ability to identify, track and monitor biomarkers associated with hematologic malignancies. These products are also being deployed worldwide to track the manufacture and treatment of immunotherapy, such as CAR T-cell therapies, and provide a comprehensive way to track a subject’s immune response to disease processes and to vaccines.
In conversations with customers and partners worldwide, we have also realized that our Research Use Only (RUO) LymphoTrack® sequencing kits and services also have utility far beyond clinical oncology, as these assays and software products are currently being used in research in areas as diverse as, studies of celiac disease and other autoimmune diseases, tracking the immune health of astronauts on the ISS, examining the immune response throughout the course of clinical treatments, and identifying changes in the immune repertoire with onset and progression of disease. Intrigued to learn what innovative applications our RUO LymphoTrack kits and services are being used for, we decided to launch this grant program to support these endeavors.
Successful innovative proposals submitted by applicants to our Invivoscribe’s Immune Biomarker Discovery grant program will receive LymphoTrack kits, controls and software to support their R&D project. Grants will be awarded to support cutting-edge research and development in academic, government and early-stage commercial laboratories conducting promising research studies.
“The combined costs of library preparation reagents, NGS sequencing reagents, and development of bioinformatics software represent an obstacle for researchers. The idea of this grant program is to reduce these financial barriers, thus empowering a few progressive laboratories to bring their groundbreaking applications to fruition,” says Tony Lialin, Chief Commercial Officer at Invivoscribe. Those selected as winners of the grant will not only receive NGS products, but will be provided additional opportunities to collaborate with Invivoscribe’s global network of ISO15189 accredited LabPMM laboratories. The laboratories selected for the grant program will also be featured in upcoming webinars and will be invited to speak at a number of symposiums around the world.
Details and How to Apply/Submit a Proposal
If your laboratory is interested in applying for Invivoscribe’s Immune Biomarker Discovery grant program to improve the standard of healthcare, we encourage you to submit research proposals that focus on the development of engineered antibodies to target antigens of infectious pathogens, toxins, allergens, and malignant diseases such as cancer and autoimmune disorders. More information about the program and details about how to submit a proposal can be found at www.invivoscribe.com/NGS-Grant. Proposals will be accepted from qualified laboratories across the world through Aug. 31, 2021 and winners will be announced by September 30, 2021. Additional information about the grant program and our oncology products and services can be requested by emailing sales@invivoscribe.com.
About Invivoscribe
Invivoscribe has been Improving Lives with Precision Diagnostics® for more than twenty-five years, advancing the field of precision medicine by developing and providing standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe has significantly impacted global health, working with pharmaceutical companies to accelerate approvals of new drugs and treatments by supporting international clinical trials, developing, commercializing companion diagnostics, and providing expertise in both regulatory and laboratory services. With its proven ability to provide global access to distributable reagents, kits, and controls, as well as clinical trial services through our international clinical lab subsidiaries (LabPMM), Invivoscribe has demonstrated it is an ideal partner. For additional information please visit us at www.invivoscribe.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005113/en/
Contact information
Tony Lialin
inquiry@invivoscribe.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ZKB in Switzerland Completes ISO 20022 Migration Using Smartstream for Reconciliations20.11.2025 12:40:00 EET | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces, Zürcher Kantonalbank (ZKB), the largest cantonal bank in Switzerland, has successfully completed its ISO 20022 migration project for reporting messages, now live with Corona MX - part of the Smart Reconciliations solutions suite. This milestone marks a significant achievement in ZKB’s digital transformation journey, as it moves to the new messaging standard, ahead of the global SWIFT migration deadline. Schmitz Wolfgang, Project Manager for ISO 20022, ZKB, states: "It has been a smooth and straightforward process working in partnership with Smartstream. The migration was executed with precision and foresight, ensuring we were fully prepared and operational well before the industry-wide ISO 20022 cutover. The solution is now live and in full production”. As a trusted partner of Smartstream for over 40 years, the bank leveraged the advanced capabilities of Corona t
PUMA Partners with Logistics Reply to Accelerate AI-Driven Innovation in Warehousing20.11.2025 12:00:00 EET | Press release
Logistics Reply, the Reply group company specialising in innovative supply chain, has extended its collaboration with global sportswear brand PUMA to further optimise daily logistics operations and enhance user experience through the integration of GaliLEA, an AI-powered assistant built on the LEA Reply™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120676732/en/ Thanks to GaliLEA, PUMA has seen significant improvements in their daily use of the LEA Reply WMS, including increased user autonomy with less reliance on external support, faster management through quick data access and assisted ticket creation, real-time operational insights for better decision-making, and streamlined logistics workflows that enhance overall system interaction. Following the successful rollout of the LEA Reply™ Warehouse Management System (WMS) across four key distribution centers in Austria, South Africa, and India between 2022 and
euNetworks Appoints Nick Walden as Chief Revenue Officer20.11.2025 11:00:00 EET | Press release
euNetworks has today announced the appointment of Nick Walden as Chief Revenue Officer, effective 02 December 2025. Nick will be based in London and will drive all facets of euNetworks’ sales and commercial strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120550034/en/ Nick Walden - CRO of euNetworks Nick joins euNetworks following 30+ years in the Telecommunications industry, most recently having led the Global Sales function for Infinera (now Nokia) as Senior Vice President – Worldwide Sales. Prior to this, Nick served as Senior Vice President & Managing Director EMEA at Infinera following over a decade of experience in leadership roles at Ciena. “It’s an incredibly exciting time to be joining euNetworks, building on their strong growth and momentum as a critical bandwidth infrastructure provider across Europe. euNetworks’ relentless customer obsession aligns closely with my passion for delivering value for cust
MVNO Europe calls on the European Commission to enable a true Single Market for mobile connectivity and Internet of Things (IoT) through the Digital Networks Act20.11.2025 10:56:00 EET | Press release
The upcoming legislative proposal for a Digital Networks Act (DNA) marks a defining moment for the European Union to build a true Single Market for electronic communications based on openness, competition and innovation. MVNO Europe believes the upcoming DNA should build on the achievements of the existing EU regulatory framework by strengthening competition among diverse providers. This competition drives innovation and delivers tangible benefits for European consumers and businesses. Ensuring genuine choice for end users is essential to maintain Europe’s global competitiveness. In light of the DNA, MVNO Europe stresses the importance of preserving and reinforcing key aspects of the European Electronic Communications Code (EECC): Maintaining the Significant Market Power (SMP) regime is essential to safeguard competition. MVNO Europe calls for the express ability to apply SMP rules to any markets, including mobile markets, as it is vital to prevent abuse of dominant market positions an
Breker Verification Systems and Frontgrade Gaisler Collaborate on High-Reliability RISC-V Fault Tolerant Processor Core20.11.2025 10:00:00 EET | Press release
Breker Verification Systems, whose portfolio solves challenges across the functional verification process for large, complex semiconductors and Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions today confirmed its RISC-V functional verification solutions were pivotal for verification of the NOEL-V, one of Frontgrade Gaisler’s fault-tolerant RISC-V processor IP cores. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120600508/en/ “The development of Frontgrade Gaisler’s IP cores is guided by a philosophy that does not tolerate design issues,” notes Jan Andersson, Director of Engineering at Frontgrade Gaisler. “This demands the most robust verification environment, something Breker’s verification solution has contributed to improve, with its broad range of tests and in-depth corner case coverage.” The ultra-high verification coverage afforded by Brek
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom